Should I Buy KRRO? KRRO 2026 Analysis

Should You Buy Korro Bio Inc (KRRO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

12.570

1 Day change

8.93%

52 Week Range

55.890

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now (speculative momentum + rerating story). Multiple upgrades and sharp price-target resets (up to $30) are driving a sentiment/positioning tailwind that can persist near-term.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
Near-term price path favors upside: current pre-market ~~12.16 is sitting just above the pivot (~~12.02); a reclaim/hold above this level keeps the next upside zone near 14.21 (R1) in play.
Options positioning is not screaming bearish (OI put-call ~1.01, zero put volume today) while implied vol is elevated—consistent with a stock that can move quickly on catalysts.

Technical Analysis

Trend/price context: pre-market 12.16 (-0.82%); trading just above the Pivot 12.023, implying the market is testing a key decision level.
MACD: histogram +0.406 (bullish), but positively contracting → upside momentum is present but cooling (more “grind higher” than “rip”).
RSI(6): 61.82 (neutral-to-slightly bullish) → not overbought; still room for continuation if buyers persist.
Moving averages: converging → consolidation after the recent move; typically precedes a breakout/breakdown, so levels matter.
Key levels: Support 12.02 (pivot) then 9.84 (S1); Resistance 14.21 (R1) then 15.56 (R2).
Pattern-based forward drift (statistical): 60% chance of modest gains: ~+0.52% next day, +4.64% next week, +1.3% next month.

Options Data

Neutral

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: Calls 3013 vs Puts 3031 → OI put/call ~1.01 (balanced to slightly defensive).
Today’s volume: Calls 47, Puts 0 → put/call volume = 0.0 (today’s flow skewed to calls, though volume is small).
Implied volatility: 154.31% (30D IV) vs 71.36% historical vol → options are pricing large moves (event-driven name).
IV percentile 75 (elevated) → sentiment/uncertainty is high; premiums are rich.
Volume vs average: today’s option volume vs 30D avg 26.7% (not a “crowded” options day yet).

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst-day fallout / story reset: KRRO-121 framed as an “independently risk-mitigated” program vs the failed KRRO-110, supporting a valuation/rating rerate.
- Heavy cluster of upgrades and raised targets (late Jan 2026): Piper ($30), Oppenheimer ($22), Cantor ($21), H.C. Wainwright ($20), Chardan ($15).
- Upcoming catalyst timeline: company plans to file for clinical trials / new drug filing path in 2H 2026 for KRRO-121 (hyperammonemia/urea cycle disorders).
- Positioning tailwind: hedge funds are reported as net buyers with buying amount up ~1445% QoQ.
- Retail sentiment shift: Stocktwits moved from bearish to extremely bullish (can amplify momentum short term).

Neutral/Negative Catalysts

- Development-stage biotech risk: KRRO-121 is still preclinical/early clinical pathway; execution and translation risk remain high.
- Overhang from prior program failure: KRRO-110 failure (delivery/LNP issues) can keep skepticism elevated even with a “reset” narrative.
- High implied volatility (154%): market expects large swings; price can gap around any update.
- Cash burn profile: ongoing losses (no durable operating profitability indicated by latest quarter).
- No politician/congress signal: no recent congress trading data available; insiders noted as neutral (no supportive buying trend).

Financial Performance

Latest quarter provided: 2025/Q3
Revenue: $1.09M, flat YoY (0.00%) → not yet showing meaningful growth.
Net income: -$18.06M, worsened -13.99% YoY → losses expanding.
EPS: -1.92, down -15.04% YoY → burn/dilution risk remains a core feature of the setup.
Gross margin: 100% (likely driven by small/atypical revenue mix; not a sign of scaled profitability).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend (Jan 27–29, 2026): strong bullish reversal with multiple firms upgrading from Neutral/Perform to Buy/Overweight/Outperform.
Price targets were raised materially (notably Piper $11 → $30; Oppenheimer to $22; Cantor $21; H.C. Wainwright $20; Chardan $15).
Wall Street “Pros” view: KRRO-121 seen as a fresh, fundamentally different shot on goal with a clearer regulatory rationale and high unmet-need indication, enabling a rerating from “post-failure” levels.
Wall Street “Cons” view: thesis depends on early-stage biology and successful clinical execution; prior delivery-related failure keeps a credibility/derisking discount until clinical data arrives.
Politicians / influential figures: no data indicating recent politician transactions; insiders reported neutral over the last month.

8 Analyst Rating

Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 25.75 USD with a low forecast of 7 USD and a high forecast of 81 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

8 Hold

0 Sell

Hold

Current: 11.540

Low

Averages

25.75

High

Current: 11.540

Low

Averages

25.75

High

Piper Sandler

Yasmeen Rahimi

Neutral -> Overweight

upgrade

$11 -> $30

AI Analysis

2026-01-29

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$11 -> $30

AI Analysis

2026-01-29

upgrade

Neutral -> Overweight

Reason

Piper Sandler analyst Yasmeen Rahimi last night upgraded Korro Bio to Overweight from Neutral with a price target of $30, up from $11, following the analyst day. Piper left with "strong conviction" for KRRO-121's probability of success. KRRO-121 is designed to reduce hyperammonemia through generation of stable, de-novo glutamine synthase variants, an approach supported by human genetic evidence, the analyst tells investors in a research note. Piper is bullish ahead of KRRO-121's nwe drug filing in the second half of 2026, saying there is a "clear precedence for a regulatory path."

Chardan

Neutral -> Buy

upgrade

$15

2026-01-29

Reason

Chardan

Price Target

$15

2026-01-29

upgrade

Neutral -> Buy

Reason

Chardan upgraded Korro Bio to Buy from Neutral with a $15 price target following the analyst day. The company says the company has "turned the page." It cites the "strong" KRRO-121 preclinical data for the upgrade.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KRRO

Unlock Now

KRRO Should I Buy

KRRO Should I Buy

Should You Buy Korro Bio Inc (KRRO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch